tiprankstipranks
Advertisement
Advertisement

HK:1672 Stock Latest News

Ascletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
Company AnnouncementsAscletis Advances Fixed-Dose Oral Obesity Pill Toward U.S. FDA IND in 2026
9d ago
1672
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
PremiumCompany Announcements
Ascletis Deepens R&D Push in Obesity Drugs as 2025 Loss Widens
15d ago
1672
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
PremiumCompany Announcements
Ascletis Pharma Sets March 31 Board Meeting to Approve 2025 Results and Consider Dividend
29d ago
1672
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
PremiumCompany Announcements
Ascletis Advances Oral Amylin Agonist ASC39 Toward U.S. IND for Obesity
30d ago
1672
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
PremiumCompany Announcements
Ascletis Posts Positive U.S. Phase II Data for Monthly GLP-1 Obesity Drug ASC30
1M ago
1672
Ascletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
PremiumCompany AnnouncementsAscletis Advances Oral Amylin Obesity Drug ASC36 Toward U.S. Clinical Trials
2M ago
1672
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
Premium
Company Announcements
Ascletis Raises HK$835 Million to Fund Global Phase III Obesity Drug Trials
2M ago
1672
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
Premium
Company Announcements
Ascletis Pharma to Raise HK$835 Million via Share Placement to Fund Obesity Drug Trials
2M ago
1672
Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
PremiumCompany Announcements
Ascletis Reports Positive Long-Term Phase III Safety Data for First-in-Class Oral Acne Drug Denifanstat
3M ago
1672
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
PremiumCompany Announcements
Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data
3M ago
1672
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
PremiumCompany Announcements
Ascletis Advances Next-Generation Once-Monthly Triple Agonist ASC37 for Obesity Into Clinical Pathway
3M ago
1672
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
PremiumCompany Announcements
Ascletis Wins FDA Green Light for Phase II U.S. Diabetes Trial of Oral GLP-1 Drug ASC30
3M ago
1672
Ascletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
PremiumCompany AnnouncementsAscletis Pharma Upsizes Share Repurchase to HK$500 Million Amid Drug Development Success
4M ago
1672
Ascletis Pharma Reports Positive Phase I Results for ASC50
Premium
Company Announcements
Ascletis Pharma Reports Positive Phase I Results for ASC50
4M ago
1672
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
Premium
Company Announcements
Ascletis Pharma’s Acne Treatment Drug Application Accepted by China NMPA
4M ago
1672
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
PremiumCompany Announcements
Ascletis Pharma’s ASC30 Shows Promising Results in Obesity Treatment Study
4M ago
1672
Ascletis Pharma Advances ASC37 for Obesity Treatment
PremiumCompany Announcements
Ascletis Pharma Advances ASC37 for Obesity Treatment
5M ago
1672
Ascletis Pharma Advances Obesity Treatment with New Co-Formulation
PremiumCompany Announcements
Ascletis Pharma Advances Obesity Treatment with New Co-Formulation
5M ago
1672
Ascletis Pharma Unveils Promising Obesity Treatment Results at ObesityWeek 2025
PremiumCompany Announcements
Ascletis Pharma Unveils Promising Obesity Treatment Results at ObesityWeek 2025
5M ago
1672
Ascletis Pharma Advances ASC36 for Obesity Treatment
PremiumCompany AnnouncementsAscletis Pharma Advances ASC36 for Obesity Treatment
6M ago
1672
Ascletis Pharma to Showcase Obesity Treatment Advances at ObesityWeek 2025
Premium
Company Announcements
Ascletis Pharma to Showcase Obesity Treatment Advances at ObesityWeek 2025
6M ago
1672
Ascletis Completes Enrollment for Phase IIa Study of ASC30 for Obesity
Premium
Company Announcements
Ascletis Completes Enrollment for Phase IIa Study of ASC30 for Obesity
6M ago
1672

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >